Beova can be prescribed at general hospitals

a new drug for the treatment of overactive bladder

Passed 22 medical institutions including SMC and AMC

Introduced copyright to Jeil Pharmaceutical and Kyorin Pharmaceutical

Beova, a new drug introduced by Jeil Pharmaceutical, will be available for Rx at general hospitals.

 

According to related industries, Beova, an overactive bladder treatment, is currently available at 22 medical institutions nationwide, including SMC and AMC, as well as advanced general hospitals, Gangnam Severance Hospital, Sangnam Sacred Heart Hospital, Dongtan Sacred Heart Hospital, Chungnam National University Hospital, and Hanyang University Hospital (headquarters, Guri).

 

Beova is a new drug introduced by Jeil Pharm from Japan's Kyorin Pharmaceuticals in November 2019.

 

It obtained domestic development, manufacturing, and sales rights, and imported raw materials to produce finished products in domestic factories.

 

In order to obtain domestic approval, Jeil Pharmaceutical conducted a phase 3 bridging clinical trial to compare and evaluate the safety and effectiveness of Beova in 210 overactive bladder patients at 20 domestic institutions, including Seoul Asan Medical Center, from May 2020 to this year.

 

As a result, it was confirmed that the change in average urination frequency per day at 12 weeks from baseline as the primary efficacy evaluation variable was improved by -2.38 times compared to -1.22 times with a placebo.

 

In the secondary endpoints, the average number of urinary urgency per day, the number of urge incontinence, the change in the number of urinary incontinence, and the change in the average voiding volume per time, there was a significant improvement compared to the placebo.

 

Beova is a new β3-adrenergic receptor agonist that selectively acts on sympathetic nerve receptors to relax the bladder detrusor muscle, helping to treat symptoms such as frequent urination, urgency, and urgency urinary incontinence.

 

Mirabegron was the only β3-adrenergic receptor agonist currently on the market, but the launch of Beova is expected to form a competitive landscape.

 

Vibegron is known to be more than 9000 times more selective for β3 receptors than β1 and β2 receptors.

 

In addition, Vibegron's maximum response rate for β3 receptors is 99.2%, which is higher than 80.4% for Mirabegron, the same β3 agonist.

 

It is an ingredient that has the advantage of having a low risk of cardiovascular side effects because it does not stimulate receptors.

 

It is known that there is very little concern about interactions with drugs that pass through the CYP2D6 metabolic pathway and that it can be administered in normal doses even to patients with hepatic or renal impairment.

 

Lee Gyu-seong, professor of urology at SMC, said, "Beova is a new drug that is introduced in Korea.

 

It will help provide high-quality treatment effects to overactive bladder patients in Korea with excellent symptom improvement and low adverse reaction rates."